Healthcare

Moleculin Biotech, Inc. experienced an unprecedented 426% increase in stock value, closing at $2.21, due to key clinical trial developments. The U.S. FDA provided essential feedback on trial designs, allowing…

Merck's stock dropped by 10% due to disappointing forecasts and declining sales. Adjusted EPS for 2025 projected between $8.88 and $9.03, below the expected $9.13. Revenue forecast of $64.1 billion…